Anergis SA, a privately held Swiss company developing immunotherapy for allergies, has received an endorsement of its technology with a CHF18 million (€14 million) Series “A” venture financing.
Paion AG more than doubled its revenue in 2010 as a result of milestone payments from three partners relating to progress in the development of desmoteplase for stroke; remimazolam for sedation and glial growth factor 2 (GGF2) for heart failure.
Sanofi-Aventis SA has fixed the terms of its offering of $7 billion of US dollar-denominated notes which will finance its acquisition of Genzyme Corp. The French multinational is acquiring the US company for about $20.1 billion.
Merck & Co Inc and Sanofi-Aventis SA have abruptly ended their agreement to create a joint animal health venture citing difficulties in getting approval from antitrust authorities in different jurisdictions in the world.
Novartis has announced the acquisition of 85% of a privately-held vaccine company in China, Zhejiang Tianyuan Bio-Pharmaceutical Co Ltd. Financial details were not disclosed. The company has an R&D and manufacturing site near Shanghai.
Chroma Therapeutics Ltd is set to receive $5 million upfront from Cell Therapeutics Inc of Seattle, Washington has part of a co-development and licensing agreement for the candidate cancer drug, tosedostat. The drug is being tested in AML.
UCB SA of Belgium has completed the placement of €300 million in perpetual subordinated bonds as part of an ongoing effort to restructure its balance sheet. The new bonds will qualify as equity, the company said.
Galápagos NV, the Belgian drug discovery and development company, achieved a net profit of €4.4 million in 2010 compared with €3 million the previous year while increasing its spending on research and development by 41% to €84.7 million.
Intercell AG, the Austrian vaccine developer, made a restructuring and impairment charge in the 2010 fourth quarter of €182.8 million, mainly as the result of terminating a vaccine patch project in Phase 3 development.
Daiichi Sankyo Co Ltd has reached an agreement to acquire Plexxikon Inc of the US, which has a product for metastatic melanoma in Phase 3, along with a companion diagnostic. The Japanese company is offering $805 million for Plexxikon.